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INTRODUCTION
The 2014 edition of the European Association for Cardio-Thoracic
Surgery (EACTS) and the European Society of Cardiology (ESC)
joint Guidelines on Myocardial Revascularization (MR) marks
the 50th anniversary of the ﬁrst coronary artery bypass grafting
(CABG) procedure [1]. The ﬁrst percutaneous coronary interven-
tion (PCI) procedure was performed 13 years later, in 1977. Since
these early times, MR techniques have gained clinical importance
worldwide and are now one of the most commonly performed
interventions in modern medicine. On the other side of the
Atlantic, the American societies have also published several guide-
lines on MR: in 2011, the ACCF/AHA Guidelines for CABG Surgery
[2]; the 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for
the diagnosis and management of patients with stable ischaemic
heart disease [3]; the 2014 ACC/AHA/AATS/PCNA/SCAI/STS
focused update [4] and in 2015, the Society of Thoracic Surgeons
(STS) Clinical Practice Guidelines on Arterial Conduits [5].
In view of the rapidly evolving landscape of therapeutic options,
this Transatlantic Editorial is intended to compare the European and
American societies’ guidelines on MR, covering important topics
such as decision-making, patient information, timing of revasculari-
zation, risk scores, ischaemia testing, revascularization with CABG
versus PCI, use of arterial conduits in CABG, on-pump versus
off-pump surgery, revascularization in diabetic patients and imple-
mentation of guidelines.
DECISION-MAKING AND HEART TEAM
The American as well as European guidelines strongly advocate
the implementation of ‘Heart Team’ decisions for complex and
stable coronary artery disease (CAD) as a class of recommendation
(COR) I, with level of evidence (LOE) C. Recommendations for
Heart Team involvement in stable multivessel CAD are stronger in
the European guidelines (‘required’) compared with the American
guidelines (‘recommended’). Furthermore, the description of the
Heart Team differs: according to the EACTS/ESC Guidelines, at
least three specialists (clinical cardiologist, interventional cardiolo-
gist and surgeon) should meet on a regular basis and protocols be
followed [1]. On the other side of the Atlantic, the American guide-
lines do not describe this multidisciplinary Heart Team in a con-
ference style, but recommend that the interventional cardiologist
and surgeon, together as a Heart Team, should discuss the treat-
ment options [3]. For centres without infrastructure for on-site cor-
onary surgery, the European guidelines recommend institutional
protocols that need to be established with partner institutions
providing surgery.
The beneﬁt of a Heart Team decision is convincingly presented
throughout all available literature in line with the authors’ atti-
tudes. The superiority of a team decision-based treatment is
derived from comparing randomized and registry cohorts with
better results for the registry cohorts [6, 7]. It has been shown that
the initiation of the structured Heart Team approach could lead to
beneﬁcial clinical outcomes [8]. Other centres report that the deci-
sion and referral strategies did not change at all after initiation
of the European guidelines, which is a clear example of how
deep-set local habits and beliefs can be and how resistant some
practitioners can be to change [9]. Interestingly, re-discussing the
same patients after 1 year leads to different decisions in 24% of
the cases. This fact underscores that, in some CAD patients, both
treatment modalities might be appropriate [10]. Also, the import-
ance of including other clinical specialists as part of the Heart
Team is reﬂected by the fact that taking the severe cases into this
conference might lead to a signiﬁcant proportion of treatment
recommendations other than MR (e.g. heart transplantation,
ventricular assist device, valve surgery or medical therapy) [8].
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PATIENT INFORMATION
Patient consent discussion is handled differently in the existing
guidelines. While the EACTS/ESC Guidelines expand on that topic in-
cluding speciﬁc recommendation categorization, informed consent
is only mentioned as a prerequisite of ‘any invasive or non-invasive
procedure’ in the American guidelines [3]. Conversely, the American
guidelines are much more precise on the topic of Patient Education.
The EACTS/ESC Guidelines put forward the importance of
patient information and need for an extensive informed consent
process. They conclude that enough time should be allowed for
informed decision-making. Speciﬁcally, in a high proportion of
patients with stable CAD, a gap between diagnostic angiography
and revascularization should exist to allow sufﬁcient time to
receive information about all therapeutic alternatives. Written
informed consent is speciﬁcally needed for all procedures done
with the exception of patients in shock or with ST-segment eleva-
tion myocardial infarction (STEMI).
TIMING
The treatment of STEMI patients with primary emergency PCI is
unquestionable. The EACTS and ESC representatives have included
this patient cohort in the joint guidelines, whereas the major
American societies have formulated separate guidelines for the
management of STEMI [11]. For those patients with non-ST-segment
elevation (NSTE)-acute coronary syndrome (ACS), the European
guidelines recommend revascularization within 24 or 72 h, accord-
ing to patient risk stratiﬁcation. Primary criteria for urgency (invasive
strategy within 24 h) are met with rising troponin levels, dynamic
ST-segment or T-wave changes or a GRACE score of >140 [1]. In the
American guidelines [2–4], the recommendation for these urgent
patients is based on a more general rule, indicating that the acuity of
presentation and extent of ischaemia dictate the timing of interven-
tion. Interestingly, both guidelines see only the need for revasculari-
zation strengthened. However, the choice of revascularization
method is mainly independent of the urgency and inﬂuenced
by the same considerations for choosing PCI or CABG in the stable
patient cohort. However, American guidelines state that PCI is rea-
sonable in patients undergoing revascularization for NSTE-ACS. Both
guidelines favour CABG over PCI for NSTE-ACS patients with dia-
betes mellitus with complex CAD.
Comparisons between American and European Guidelines for
patients with NSTE-ACS are outlined in Table 1.
For stable patients without severe symptoms, the EACTS/ESC
Guidelines consider a maximum waiting time of 6 weeks to revas-
cularization appropriate. Whenever symptoms are severe,
Table 1: ACCF/AHA and EACTS/ESC Guidelines on NSTEMI
ACCF/AHA 2011 (Hillis [2])
and 2012 (Fihn [3])
ACC/AHA 2014 focused update
(Amsterdam [12])
ESC 2011 (Hamm [13]) EACTS/ESC 2014 (Kolh [1])





Class I : PCI versus CABG with
multivessel disease or complex
lesions should be discussed with
Heart Team
Class IIb (LOE B). A strategy of
multivessel PCI, in contrast to
culprit-only PCI, may be
reasonable in patients undergoing
coronary revascularization as part
of treatment for NSTE-ACS
Class I (LOE C). The revascularization
strategy (ad hoc culprit lesion
PCI/multivessel PCI/CABG)
should be based on the clinical
status as well as the disease
severity (SYNTAX score),
according to the Heart Team
protocol
Class I (LOE C). It is recommended
to base revascularization strategy
(ad hoc culprit lesion PCI
multivessel PCI/CABG) on clinical
status and comorbidities as well
as disease severity (SYNTAX)




Class IIa (LOE B). Reasonable to
choose CABG over PCI in older
(≥75 years) patients with
NSTE-ACS who are appropriate
candidates, DM, three-vessel CAD
(SYNTAX >22) with or without
involvement of proximal LAD to
decrease events and readmission,
and improve survival
Class I (LOE B). CABG should be
favoured over PCI in diabetic





Class IIa (LOE B) PCI for
unstable angina/NSTEMI
if not a CABG candidate
Class I (LOE C). Recommend to base
revascularization strategy on
clinical status and comorbidities
as well as the disease severity
(SYNTAX) according to the local
Heart Team protocol
ACCF: American College of Cardiology Foundation; ACS: acute coronary syndrome; AHA: American Heart Association; CABG: coronary artery bypass grafting;
CAD: coronary artery disease; DM: diabetes mellitus; EACTS: European Association for Cardio-Thoracic Surgery; ESC: European Society of Cardiology; LAD: left
anterior descending; LM: left main; LOE: level of evidence; NSTEMI: non-ST-segment elevation myocardial infarction; PCI: percutaneous coronary
intervention.
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anatomy high-risk or left ventricular function depressed, the
European guidelines recommend revascularization within 2 weeks
[1]. Interestingly, the American guidelines do not cover this
problem. The waiting times in American centres appear to have
been reduced and this topic might not be of the same signiﬁcance
as in previous years [14]. Also, differences in payer systems in
Europe and America contribute to timing considerations. In add-
ition, cultural and social expectations are likely to be different
among patients and cardiologists across the Atlantic.
RISK SCORES
Various risk scores validated for the short-term mortality after
CABG are available (STS score, EuroSCORE and EuroSCORE II,
ACEF), but these scores do not predict medium- or long-term
outcome. The SYNTAX score was developed to summarize the
complexity of coronary lesions [15]. It was found that medium-
and long-term outcomes correlated with the SYNTAX score. Both
guidelines see an important role of using risk scores—especially
the SYNTAX score. The American guidelines provide a COR IIa
(LOE B) for the use of STS and SYNTAX scores in patients with
complex CAD and unprotected left main (LM) disease, whereas
the EACTS/ESC Guidelines recommend the use of the SYNTAX
score to assess medium- to long-term outcome before CABG or
PCI (COR I, LOE B). The STS score (COR I, LOE B) or the EuroSCORE
II (COR IIa, LOE B) should be used to assess short-term outcome
after CABG. Also, some recommendations in the choice of treat-
ment modality are based on the SYNTAX score in the guidelines
(see speciﬁc paragraph). Of note, limitations exist in all risk models
and the performance in the speciﬁc centre’s patient cohort should
be taken into consideration. The risk scores should only be used
as an adjunct, whereas the Heart Team’s decision based on the
clinical proﬁle remains essential.
ISCHAEMIA TESTING
The EACTS/ESC Guidelines recommend diagnostic testing in stable
CAD only in symptomatic patients and based on the probability
of signiﬁcant disease. In patients with intermediate probability
(15–85%) of signiﬁcant disease, functional testing using stress echo-
cardiography, nuclear imaging, stress MRI or PET perfusion scan is
recommended (COR I, LOE A for all four modalities), while CT angi-
ography should be considered (COR IIa, LOE A). In case of higher
probability, coronary angiography is recommended (COR I, LOE A).
Exercise electrocardiogram (ECG) is not mentioned.
The American guidelines delve into the recommendation of diag-
nostic tests in greater detail, which are presented in an algorithm [3].
Taking together the COR I from the algorithm, they recommend the
use of exercise ECG in those patients with interpretable ECG (COR I,
LOE A). In patients with non-interpretable ECG, exercise test with
nuclear imaging or echocardiography is advocated (COR I, LOE B).
In patients unable to exercise, pharmacological stress nuclear
imaging or echocardiography should be performed (COR I, LOE B).
CT angiography should be considered (COR IIa, LOE C) in several




With the 5-year results of the SYNTAX trial showing a clear survival
beneﬁt for several surgical subgroups [16], the European guidelines
focus very precisely on the grading of the complexity of the coron-
ary disease according to the original SYNTAX score. Thus, these
guidelines give a clear COR I (LOE A or B) for surgery of any coronary
disease exhibiting proximal left anterior descending (LAD) coronary
artery stenosis, any three-vessel disease and any LM stenosis.
However, PCI is recommended as an alternative for patients with
one- and two-vessel disease with proximal LAD involvement, LM
disease with a low SYNTAX score and three-vessel disease also with
a low SYNTAX score. Conversely, PCI should not be used (COR III) in
patients with LM disease and high SYNTAX score or with three-
vessel disease and intermediate or high SYNTAX score.
The American guidelines, in general, appear more liberal with
the use of PCI in patients with three-vessel disease when low or
intermediate complexity is present and more restrictive when LM
disease is involved. They are not so closely structured according to
the SYNTAX score or other means representing the complexity of
the coronary anatomy. Rather, a subset of clinical scenarios is
taken into consideration.
Comparisons between American and European guidelines for
patients with stable CAD are detailed in Table 2.
Figures 1 and 2 show suggested algorithms, in patients with
stable CAD without or with LM coronary artery involvement, to
help simplify the decision-making process and to possibly avoid
the need for systematic discussion of every patient with locally
agreed protocols (adapted from 2013 ESC Guidelines on the man-
agement of stable CAD) [17].
BILATERAL INTERNAL MAMMARY ARTERY
Although nicely presenting the physiological basis for improved
graft patency with arterial versus saphenous vein (SV) bypass con-
duits, the ACCF/AHA Guidelines are remarkably conservative in
their recommendations. Although a large number of studies had
already been published supporting the survival beneﬁt of bilateral
versus single IMA grafting, the writing committee elected to quote
only studies from a single centre in a very subdued recommenda-
tion stating that ‘when anatomically and clinically suitable, use of a
second IMA to graft the left circumﬂex or right coronary artery is
reasonable to improve the likelihood of survival and to decrease
reintervention rate’ (COR IIa, LOE B). Oddly enough, the studies
cited to support this recommendation, although carefully per-
formed, reported neither the largest, least selective, nor longest
followed patient cohorts available in the literature at the time of
guideline generation [18, 19]. Clearly, the absence of prospective
randomized control trial (RCT) data may have inﬂuenced the task
force’s recommendations, despite the physiologically sound and
increasingly clinically robust evidence supporting bilateral internal
mammary artery (BIMA) grafting. The discussion of the risk of
sternal wound infection was not referenced, despite extensive lit-
erature on the topic, and no mention was made on the potential
impact that the ‘skeletonized’ technique for IMA harvest may have
on reducing the risk of sternal infection.
The European guidelines, on the other hand, perhaps due to a
large number of supportive studies that have emerged in the years
between the release of these two sets of guidelines [18, 19], are
much more supportive of the use of bilateral IMA grafting. The
authors speciﬁcally address the decreased risk of sternal infection
(as well as other potential beneﬁts) with the skeletonized ap-
proach to IMA harvest, and directly address the potentially
increased risk of mediastinitis, particularly in diabetics and obese
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Table 2: ACCF/AHA and EACTS/ESC Guidelines on Myocardial Revascularization
Guidelines for myocardial revascularization to improve survival in stable ischaemic disease
ACCF/AHA 2011 (Hillis [2]) and 2012 (Fihn [3]) ACC/AHA 2014 focused update
(Fihn [4])
EACTS/ESC 2014 (Kolh [1])
Unprotected LM or
complex CAD
Class 1 (LOE C): Heart Team approach
recommended
Multidisciplinary decision-making required
for multivessel stable CAD
Class IIa (LOE B): calculation of STS and SYNTAX
score
Class I (LOE C). Institutional protocols
are developed by the Heart Team to
implement appropriate revascularization
strategy in accordance with guidelines
Unprotected LM Class I (LOE B): CABG recommended Class I (LOE B): CABG for LM and
SYNTAX ≤22
Class IIa (LOE B): PCI for stable ischaemic heart
disease when both: low-risk PCI procedural
complications with high likelihood of
long-term outcome (SYNTAX ≤22, ostial or
trunk LM) and clinical characteristics predict
significantly increased risk of adverse surgical
outcomes (STS predicted operative mortality
≥5%)
Class I (LOE B) for PCI
Class IIb (LOE B): PCI when both: anatomical
conditions associated with low–intermediate
risk PCI procedure complications and
intermediate to high likelihood of good long-
term outcome (SYNTAX <33, bifurcation LM
CAD) and clinical characteristics that predict
increased risk of adverse surgical outcomes
(moderate-severe COPD, disability from prior
stroke, prior cardiac surgery) (STS predicted
operative mortality >2%)
SYNTAX 23–32
Class I (LOE B): CABG
Class IIa (LOE B): PCI
Class III (LOE B): harm when PCI chosen in
patients with unfavourable anatomy for PCI
and who are good candidates for CABG
SYNTAX >32
Class I (LOE B): CABG





Class I (LOE B): CABG SYNTAX ≤22
Class I (LOE A): CABG
Class I (LOE B): PCI
• Class IIa (LOE B): CABG reasonable over PCI
with complex three-vessel CAD (SYNTAX >22)
who are good candidates for CABG
• Class IIb (LOE B): PCI of uncertain benefit
SYNTAX 23–32
Class I (LOE A): CABG
Class III (LOE B): harm PCI
SYNTAX >32
Class I (LOE A): CABG




Class I (LOE B): CABG
Class IIb (LOE B): PCI uncertain benefit
Class I (LOE B): CABG




Class IIa (LOE B): CABG with extensive ischaemia
Class IIb (LOE C): CABG of uncertain benefit
without extensive ischaemia
Class IIb (LOE B): PCI of uncertain benefit
Class IIb (LOE C): CABG
Class I (LOE C): PCI
One-vessel proximal
LAD
Class IIa (LOE B): CABG with LIMA for long-term
benefit
Class I (LOE A): CABG
Class IIb (LOE B): PCI uncertain benefit Class I (LOE A): PCI
One-vessel without
proximal LAD
Class III (LOE B): harm when CABG chosen
Class III (LOE B): harm when PCI chosen
Class IIb (LOE C): CABG
Class I (LOE C): PCI
Continued
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Table 2: Continued
Guidelines for myocardial revascularization to improve survival in stable ischaemic disease
ACCF/AHA 2011 (Hillis [2]) and 2012 (Fihn [3]) ACC/AHA 2014 focused update
(Fihn [4])
EACTS/ESC 2014 (Kolh [1])
Diabetic patients Class IIa (LOE B): CABG reasonable over PCI to
improve survival in patients with multivessel
CAD and DM, particularly if LIMA used to
LAD
Class I (LOE B): CABG is generally
preferred versus PCI to improve
survival in patients with DM and
multivessel CAD for which
revascularization is likely to
improve survival (three-vessel
CAD or complex two vessel CAD
involving proximal LAD),
particularly if LIMA can be
anastomosed to LAD, provided
a good candidate for surgery
Class I (LOE A): patients with multivessel
CAD and acceptable surgical risk, CABG
recommended over PCI
Class IIa (LOE B): patients with multivessel
CAD and SYNTAX ≤22, PCI should be
considered as alternative to CABG
Class I (LOE C): a Heart Team
approach to revascularization is
recommended in patients with
DM and complex multivessel
CAD
ACCF: American College of Cardiology Foundation; ACS: acute coronary syndrome; AHA: American Heart Association; CABG: coronary artery bypass grafting;
CAD: coronary artery disease; DM: diabetes mellitus; EACTS: European Association for Cardio-Thoracic Surgery; ESC: European Society of Cardiology; LAD: left
anterior descending; LIMA: left internal mammary artery; LM: left main; LOE: level of evidence; PCI: percutaneous coronary intervention; STS: Society of
Thoracic Surgeons.
Figure 1: Percutaneous coronary intervention or coronary artery bypass graft surgery in stable coronary artery disease without left main coronary artery involvement.
CABG: coronary artery bypass grafting; LAD: left anterior descending; PCI: percutaneous coronary intervention. a>50% stenosis and proof of ischaemia, >90% stenosis
in two angiographic views or fractional ﬂow reserve <0.80. bCABG is the preferred option in most patients unless patients’ comorbidities or speciﬁcities deserve discus-
sion by the Heart Team. According to local practice (time constraints and workload), direct transfer to CABG may be allowed in these low-risk patients, when formaI
discussion in a multidisciplinary team is not required [adapted from ESC/EACTS Guidelines on Myocardial Revascularization 2010; reproduced from [17] with permis-
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the text, conclude that ‘BIMA grafting is recommended if life ex-
pectancy exceeds 5 years and to avoid aortic manipulation’.
However, in framing the guideline itself, the authors opted for a
more conservative tone: ‘Bilateral IMA grafting should be consid-
ered in patients <70 years of age’, as a COR IIa, LOE B. What is
perhaps interesting is that both sets of guidelines classify the rec-
ommendation as a COR IIa, LOE B with similar deﬁnitions: ACCF/
AHA, ‘Beneﬁt >> Risk, It is reasonable, additional studies needed’;
ECS/EACTS, ‘Weight of evidence in favor, should be considered’.
Clearly, the data that will emerge from the only prospective RCT
on the topic will be eagerly awaited, although, as with any good
study, it is likely to raise as many questions as it answers [20].
RADIAL ARTERY
This comparison is based on the 2011 ACCF/AHA Guidelines for
CABG Surgery [2], in concert with the 2014 ESC/EACTS Guidelines
on MR [1]. As a general comment, the European guidelines are
more procedurally directive than the American guidelines. The
2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update [4] does not
contain any new guidelines with respect to radial artery (RA) graft-
ing. The STS has recently published Clinical Practice Guidelines on
Arterial Conduits that do address the RA [5]. The recommendations
of the STS Practice Guidelines regarding RA grafting will be outlined
as well.
The 2011 ACCF/AHA Guidelines contain a single COR IIb (i.e.
may be considered), based on LOE B, for the use of the RA for
CABG. Speciﬁcally, the recommendation emphasizes the import-
ance of a severe proximal stenosis when using an RA, which was
deﬁned as left-sided stenosis of >70 or >90% (i.e. critical) for a
right-sided target vessel. The text is short, but emphasizes that RAs
are prone to spasm and/or atrophy when directed to a moderately
rather than a severely narrowed coronary artery. It is well recog-
nized that arterial grafts including the RA may fail not only by oc-
clusion but can also remain patent while becoming extremely
narrowed and non-functional (string sign) [21]. Evidence exists that
the RA is probably more dependent on the severity of the prox-
imal target vessel stenosis than the IMA [22, 23]. The 2011 ACCF/
AHA Guidelines also include a further COR III, LOE C, regarding
the importance of not grafting the right coronary artery with an
arterial graft (RA not speciﬁcally mentioned), unless it has a critical
stenosis.
The 2014 ESC/EACTS Guidelines were written following the
publication of several additional important randomized and ob-
servational studies concerning RA grafting [24–26]. One table in
these guidelines summarizes the early, mid and late patency of
the RA in addition to SV grafts and left and right IMAs—RA
patency exceeds that of SVs but is likely less than the left or right
IMA [1]. Also, late survival and event-free survival are enhanced.
Consequently, these recent guidelines more strongly recommend
the RA (COR I, LOE B) than the American guidelines, but again, like
the American guidelines, emphasize the importance of a high-
grade stenosis of the native coronary artery. The guidelines do not
stipulate the severity; however, in the text, the authors describe
that patency of the RA is strongly affected for lesions <70%. In the
text, the writers conclude that the RA is a reasonable alternative
for a second arterial graft when BIMA harvesting is contraindi-
cated due to increased risks of sternal infection.
The very recent STS Practice Guidelines [5] recommend a Heart
Team approach for decisions regarding revascularization, includ-
ing the type of grafts (COR I, LOE C). The STS Practice Guidelines
Figure 2: Percutaneous coronary intervention or coronary artery bypass graft surgery in stable coronary artery disease with left main coronary artery involvement.
CABG: coronary artery bypass grafting; PCI: =percutaneous coronary intervention. a>50% stenosis and proof of ischaemia, >70% stenosis in two angiographic views or
fractional ﬂow reserve <0.80. bPreferred option in general. According to local practice (time constraints and workload), direct decision may be taken without formal
multidisciplinary discussion, but preferably with locally agreed protocols [adapted from ESC/EACTS Guidelines on Myocardial Revascularization 2010; reproduced
from [17] with permission of Oxford University Press (UK) © European Society of Cardiology, www.escardio.org/guidelines].
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recommend a second arterial graft, either a second IMA or an RA
(COR IIa, LOE B in appropriate patients), recognizing that patient
comorbidities affect the risks and relative beneﬁts of different
approaches. Again, the RA should be directed to a coronary artery
with a severe stenosis (COR IIa, LOE B); in addition, pharmaco-
logical dilatation is recommended intraoperatively and periopera-
tively (COR IIa, LOE B), but there is insufﬁcient evidence to warrant
any recommendation regarding longer-term use of pharmaco-
logical dilatation.
The American and European scientiﬁc societies recognize the
prognostic importance of the severity of target vessel stenosis for
radial graft patency based on visual assessment by coronary
angiogram. Physiologically rather than anatomically deﬁned sten-
osis as assessed by fractional ﬂow reserve (FFR) has prognostic im-
portance in percutaneous revascularization, and both the
American and European guidelines recommend this practice for
PCI [27–32]. There is some evidence that FFR-guided coronary
surgery is associated with improved graft patency [33, 34].
Whether FFR, or FFR in association with anatomical severity will
supplant visual assessment for radial grafting speciﬁcally, or coron-
ary surgery in general, is unclear at this stage.
TOTAL ARTERIAL REVASCULARIZATION
In a somewhat uncharacteristic fashion, the issue of total arterial
revascularization (TAR) is mentioned in the ACCF/AHA Guidelines
as a COR IIb (LOE C)—‘may be reasonable in patients ≤60 years of
age with few or no comorbidities’—without further discussion or
reference to any speciﬁc literature. A similar lack of direct discus-
sion of the topic is apparent in the European guidelines, although
two recommendations are made: one supporting TAR for patients
with poor vein quality (COR I, LOE C, without reference, presum-
ably based on logical and prior recommendations for complete
revascularization), and the other advocating that TAR should be
considered in patients with reasonable life expectancy (COR IIA,
LOE B) based on a single reference [35]. Although thorough in its
practical exploration of potential conduits, only two studies were
cited in this article, which directly addressed the issue of TAR [36,
37]. Perhaps, the reticence of the guideline writing committees
reﬂects the relative paucity of data on the topic. Although consid-
erable clinical data support the use of multiple arterial grafting,
TAR only comprises a small portion of such reports [36–39].
Comparisons are usually with single IMA grafting strategies, and
differential use of IMAs and RAs, as well as the issue of in situ
versus free Y and T grafting, make comparisons difﬁcult. Concerns
regarding the use of RAs, which have been used for interventional
procedures, further complicate the issue [40]. The major question
emerging is whether or not a strategy of TAR provides incremental
beneﬁt compared with BIMA or even single IMA/RA grafting.
Reports to date have been encouraging but inconsistent [41–43].
Clearly, more compelling data will be needed to warrant
guideline-based changes in practice.
ON- VERSUS OFF-PUMP
Although the ACC, AHA and associated societies have performed
a recent focused update for the diagnosis and management of
patients with stable ischaemic heart disease [4], this did not
address the issues of off-pump and on-pump CABG, and optimal
conduit selection. Therefore, the comparisons and comments
on these topics are solely based on the 2011 ACCF/AHA
Guidelines for CABG Surgery [2] and the 2014 ESC/EACTS
Guidelines on MR [1].
The ACCF/AHA Guidelines directly address the use of cardio-
pulmonary bypass (CPB) as well as the more speciﬁc issue of
off-pump versus on-pump CABG. Interestingly however, despite a
somewhat scholarly review of the physiological basis for the
Systemic Inﬂammatory Response Syndrome (SIRS) and its poten-
tial clinical sequelae, especially as regards neurocognitive and
renal dysfunction, and a focused review of the available evidence
comparing on- and off-pump approaches, the writing committee
elected to offer no guideline recommendations regarding either
issue. Multiple strategies for mitigating potential mediators of
surgical morbidity, most speciﬁcally as regards renal and neuro-
logical dysfunction—cell-saver processing of shed blood, modulat-
ing neutrophil activation, steroid and immunoglobulin G
administration, use of coated and/or mini-CPB circuits—were all
mentioned without convincing arguments supporting their efﬁ-
cacy. It is perhaps this absence of compelling evidence that has
prompted the European colleagues to avoid directly addressing
the topic.
Regarding the issue of off- versus on-pump approaches to
CABG surgery, the ACC/AHA writing committee was clearly con-
cerned by the apparent disparities in the data. The equipoise of
early small, prospective RCTs [44, 45] and the negative ﬁnding of
the somewhat controversial ROOBY trial [46] have left the authors
with an exploration of registry data which was equally inconclu-
sive, even in the high-risk patient population [47–49]. The con-
cluding remarks focused on the avoidance of aortic manipulation,
regardless of an on- versus off-pump approach in patients with
evidence of aortic atherosclerotic disease, acknowledging that this
may be more readily achieved with an off-pump approach. It was,
however, noted that patients with unstable haemodynamics may
be more readily managed with an on-pump approach. In short, al-
though there may be patients for whom one approach or the
other may be preferable, given adequate surgical expertise, ‘most
surgeons consider either approach to be reasonable for the ma-
jority of subjects undergoing CABG’, no formal recommendation
was given.
The European Task Force, on the other hand, had the beneﬁt of
more robust data. Two additional prospective RCTs, focusing on
elderly and high-risk patients, had failed to demonstrate a differ-
ence in 30-day or 1-year outcomes when on- or off-pump CABG
was performed by experienced teams [50, 51]. Interestingly, based
on some of the same data available to the American group [47,
52], the Europeans were more convinced of the potential value of
off-pump surgery in high-risk patients, especially with regard to
stroke, and recommended that off-pump CABG be ‘considered’
for subgroups of high-risk patients in high-volume off-pump
centres as a COR IIa based on LOE B. Like their American collea-
gues, the European group was even more deﬁnitive regarding
minimization of aortic manipulation and ‘recommended’
off-pump CABG and/or no touch on-pump techniques for
patients with signiﬁcant atherosclerotic aortic disease as a COR I
with LOE B.
Subsequent studies have suggested that complexity of the issue
may revolve around surgical expertise and patient selection, in
that the short-term potential beneﬁts for off-pump need to be
balanced against the long-term apparent beneﬁts for the
on-pump approach. The reduced graft patency, demonstrated in a
meta-analysis of RCTs [53], seems consistent with data emerging
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100 000 patients, which demonstrated a worse 5-year survival
among off- as opposed to on-pump patients [54]. Interestingly,
current evidence suggests that the difference in graft patency may
be limited to SV grafts, suggesting a potential role for increased
use of arterial conduits regardless of the CPB strategy employed.
Hopefully, by the time the current guidelines are updated, better
evidence will be available to identify, in equally experienced
hands, which patients are mostly likely to beneﬁt from which
approach.
MINIMALLY INVASIVE DIRECT CORONARY
ARTERY BYPASS AND HYBRID
REVASCULARIZATION
Neither the 2011 American guidelines [2] nor the subsequent
update [4] included any recommendations regarding minimally
invasive surgery. The 2014 European guidelines [1] did advise that
minimally invasive direct coronary artery bypass (MIDCAB) be
considered for isolated LAD disease (COR IIa, LOE C). In the text,
the writers concede that while the safety and efﬁcacy of MIDCAB
are similar to that achieved with conventional on- or off-pump
coronary surgery, these approaches do achieve beneﬁts in terms
of shorter length of hospital stay and a better quality of life early
following surgery. The text in the American guidelines acknowl-
edges the potential beneﬁts of a minimally invasive approach,
namely avoidance of sternal complications, earlier recovery and
enhanced cosmesis, and also mentions robotic-assisted, endo-
scopic approaches as the most minimally invasive technique [55].
However, the 2011 American guidelines focus mainly on the lim-
itations of a small anterolateral thoracic incision (or other incisions
short of a full sternotomy), in terms of lack of exposure of all cor-
onary territories and the aorta.
Efforts to provide complete revascularization with minimal sur-
gical incisions have led to interest in hybrid revascularization—
namely isolated LAD bypass with an IMA graft and stenting of the
right coronary artery and/or circumﬂex artery territories, either
simultaneously, or as a staged procedure. Hybrid revascularization
acknowledges the relative beneﬁt of an IMA for LAD revasculariza-
tion, and the reduced invasiveness of PCI for non-LAD targets, in
concert with the progressively improved results of PCI, particularly
with later-generation drug-eluting stents. Although hybrid revas-
cularization is commonly understood to involve a minimally inva-
sive approach for left internal mammary artery (LIMA)–LAD
bypass (MIDCAB, robotic), a full sternotomy for LIMA–LAD bypass
in conjunction with PCI is compatible with the deﬁnition [56], and
likely to be utilized by surgeons more often than one of the min-
imally invasive methods [57].
Consequently, the American guidelines do include speciﬁc
recommendations on hybrid revascularization. The American
guidelines recommend hybrid revascularization as COR IIa, LOE B
in multivessel disease patients when conventional surgical revas-
cularization or PCI is anticipated to be more challenging or haz-
ardous [58], for surgical patients due to a hostile aorta and/or poor
targets and/or limited conduit, and for PCI patients when percu-
taneous revascularization of the LAD is expected to be problemat-
ic due to local angiographic features. The American guidelines do
make a further COR IIb, LOE C as an alternative to CABG or PCI—
this approach is intended to minimize risk and improve the bene-
ﬁts relative to isolated PCI or CABG. Presumably, a Heart Team
would help make such a decision although the writers did not
further elaborate on the context of this recommendation.
Whereas the European guidelines are generally more directive
about procedural aspects of revascularization, they only suggest
that hybrid approaches may be considered in speciﬁc patient
cohorts and in experienced institutions (COR IIb, LOE C). In the
text, it becomes clearer that the authors have adopted a broader
interpretation of hybrid revascularization by including not only
patients treated with coronary surgery and PCI, but also PCI and
other cardiac operations. The European writing committee did
make a strong recommendation to avoid aortic manipulation in
patients with a very hostile ascending aorta, COR I, LOE B. The
data supporting or refuting the MIDCAB and hybrid revasculariza-
tion approaches are substantially more limited than for other pro-
cedural aspects of coronary bypass surgery [57].
DIABETIC PATIENTS
The importance of diabetes mellitus in the selection of revascular-
ization strategy was recognized in the 2014 ACC/AHA/AATS/
PCNA/SCAI/STS focused update [4] and the 2014 ESC/EACTS
Guidelines on MR [1] (Table 2). While both sets of guidelines con-
sider CABG to be a COR I in diabetics, the European authors
provide a COR IIa for PCI in diabetics with low SYNTAX scores.
Beyond the recommendation for use of the LIMA to LAD, the
American guidelines do not delve into the issue of how diabetes
might inﬂuence surgical grafting strategy. The European task force
directly discusses the potential impact of BIMA grafting on the
diabetic patient and suggests that BIMA grafting should be consid-
ered (COR IIa, LOE B). Although both sets of guidelines express
concern regarding the potential for increased risk of sternal
wound infection with IMA harvest in diabetic patients, it was not
until the recent release of the STS Clinical Practice Guidelines on
Arterial Conduits for CABG [5] that speciﬁc strategies for reducing
this risk through the use of a ‘skeletonized’ harvest approach is dir-
ectly addressed as a COR IIa, LOE B.
Although diabetes is an established risk variable for infection,
the risk of radial harvest site infection is low, with or without dia-
betes. Diabetes was associated with an increased risk of graft oc-
clusion at 1 year and 7.5 years postoperatively in the RAPS studies
[59, 60]; however, the use of an RA compared with SV grafting was
associated with reduced graft occlusion in the diabetic cohort. In
observational studies, the use of an RA as a second arterial
conduit proved to be protective in terms of late survival [61, 62].
GUIDELINES AND TREATMENT REALITY
Surgeons in numerous countries have complained about an un-
controlled overuse of PCI over CABG with ever-increasing rates of
PCI use and falling numbers of isolated CABG procedures, particu-
larly for stable ischaemic heart disease. In this regard, the report
of the OECD (Organization for Economy Cooperation and
Development) gives more speciﬁc information on the use of
revascularization techniques in the different European countries,
the USA and some other selected nations. An average rate of 218
coronary revascularization procedures per 100 000 population is
reported with an average PCI proportion of 72% performed in
2013 [63]. Across countries, there is a tremendous variation in
these ﬁgures, with the highest revascularization rate of about 435
procedures per 100 000 in Germany, triggered by the enormous
rate of PCI (roughly 360 per 100 000) resulting in a PCI proportion
of 84%. A closer look at the nationally published annual data [64,
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65] suggests an even greater disparity in the rates of PCI and
CABG. For example, in Germany, an absolute number of 40 000
isolated CABGs and 360 000 PCIs were reported in 2014, yielding
a PCI/CABG ratio of 9 : 1.
In the USA, Appropriate Use Criteria for coronary revasculariza-
tion were published in 2009 [66]. The overall rates of PCI have
declined in the USA subsequent to the publication of the
Appropriate Use Criteria [67, 68]—this drop is entirely related to a
substantial decrease in the rates of PCI for stable or non-acute is-
chaemic heart disease, while the rates for acute indication have
remained stable. Furthermore, the proportion of PCI procedures
judged to be inappropriate has declined as well [68].
The fundamental differences in the worldwide use of PCI and
CABG may be caused by different healthcare system structures
with limitations in capacity and access to treatment options in the
health service or may be driven by reimbursement forces and ﬁ-
nancial aspects. To what extent and under which conditions revas-
cularization procedures are performed under adherence to the
relevant European and American CAD guidelines cannot be sub-
stantially evaluated on the basis of most national data sources.
Necessary items like the treatment of three-vessel disease and/or
LM stenosis, as well as distinction between stable CAD and acute
MI, are not systematically monitored in parallel to the guidelines
although medical quality assessment systems are established in
the majority of the mentioned countries.
The use of a Heart Team approach—strongly indicated in the
guidelines from both sides of the Atlantic— should partially
address the concern regarding the overuse of PCI versus CABG.
However, the extent to which a formal Heart Team involvement
or institutional protocols are applied, as recommended in the
guidelines, remains unclear. To improve guideline implementa-
tion and prevent malpractice, it is of major importance in the
future to apply mandatory, more speciﬁc data sets in quality as-
sessment and allow for the required transparency and control.
Even more formal measures comparable to structured tumour
boards in oncology and reimbursement of treatment depending
on guideline adherence should be put under consideration.
CONCLUSIONS
With this editorial, we could convincingly outline a broadly coher-
ent similarity between the 2011 ACCF/AHA Guidelines for CABG
Surgery, including supplementary updates over the recent years,
and the 2014 ESC/EACTS Guidelines on MR. Whenever the same
patient cohorts were mentioned, the American and European
guidelines present astonishingly similar major recommendation in
at least 6 occasions. Another 11 major recommendations are
slightly different, albeit pointing clearly in the same direction. We
identiﬁed only two instances in which the guidelines present
meaningfully different recommendations, which most certainly
were related to the time gap in between the creation of the two
sets of guidelines.
Particularly for areas of highest controversy between surgeons
and cardiologists, the recommendations for revascularization of
three-vessel disease and LM disease in stable coronary heart
disease, a high level of concordance between both guidelines was
demonstrated, even though the timing of guidelines release dif-
fered in the basic versions by 3 years. Thus, the ESC/EACTS
Guidelines are, in fact, more contemporary and relevant as they
incorporate the 5-year results of the SYNTAX trial and more
recent meta-analyses on studies for multivessel revascularization
and LM procedures. Besides very speciﬁc recommendations in-
cluding the complexity of the coronary ﬁndings, there is general
consensus in recommending bypass surgery either as an equiva-
lent alternative or preferential procedure compared with PCI,
whenever a signiﬁcant proximal LAD stenosis is present.
The practical and scientiﬁc value of both guidelines is undoubt-
edly proved by a worldwide endorsement through the speciﬁc
cardiological and cardio-surgical medical societies, even outside
the USA and Europe, often with additional independent national
guidelines adopting these recommendations. However, it has also
become evident that there is a signiﬁcant numeric imbalance in
total rates and proportion of the applied techniques by ofﬁcial
healthcare ﬁgures; allegations of PCI overuse have frequently
been suggested by surgeons, non-invasive cardiologists and
general practitioners, on the one hand, or even by health insur-
ance companies in the interest of patient care, on the other.
To achieve medically reasonable diagnostics and treatments as
proposed by medical guidelines along with cost-effective distribu-
tion of healthcare resources in the cardiovascular health system,
it is mandatory to achieve transparency and control under condi-
tions of systematic and reliable data monitoring and reporting
systems in parallel to the major decision-making criteria being
used for stratiﬁcation according to the treatment algorithms. For
practical use, the application of either institutional protocols or in-
dividual case-by-case Heart Team decisions is strongly dependent
on the conﬁdence and quality of collaboration between the inter-
ventional and non-interventional cardiologists and the cardiac
surgeons. Especially in institutions with obvious disagreement or
malfunction, a regulatory role of the hospital administration or
even of state healthcare organizations may be necessary to ensure
correct guideline implementation in the interest of evidence-
based medicine.
The ultimate goal of guidelines is to create a framework to facili-
tate patient-focused care. To this end, US and European cardio-
vascular specialty societies strongly recommend a Heart Team
approach (COR I). Marked regional variation in the rates of differ-
ent medical interventions, such as the ratio of PCI to coronary
bypass operations, is usually unrelated to patient differences but
rather differences in health practitioner behaviour or healthcare
systems. A marked change in the pattern of practice of PCI for
stable ischaemic heart disease in the USA followed the publication
of the Appropriate Use Criteria, showing that physician behaviour
can change with appropriate incentives. Creating systems with ap-
propriate inducements at the hospital or regional/national level,
or along with private insurers where appropriate, should ensure
that adherence is high.
There is a sense in the global cardiac surgical community that
revascularization decision-making is not evidence-based. Heart
Teams can initiate patient discussions using the treatment algo-
rithms as outlined in the revascularization guidelines—however as
doctors, clinical decision-making typically requires a more com-
prehensive understanding of the unique characteristics of the in-
dividual patient. For patient-focused care, each specialty needs to
hear the other colleague’s viewpoint. When this fails to happen,
we need to remain cognizant of the fact that it is the patient who
ultimately loses from dysfunctional interactions—market share is
not the issue. And remember that cardiologists and cardiac
surgeons are on the same team—the Heart Team.
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